Jack Anders - 01 Sep 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: RVMD
Reported as of: 01 Sep 2023
Net transaction value: -$647,492
SEC form: 4
Accepted by SEC: 06 Sep 2023, 20:02:45 UTC
Prior SEC filing: 22 Jun 2023
Next SEC filing: 20 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 06 Sep 2023.

Key facts

This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Sep 2023, 20:02.

Change

Previous filing in this sequence was filed on 22 Jun 2023.
Current net transaction value: -$647,492.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Options Exercise

Transaction value: $53,600
Shares: +20,000
Change %: +36%
Price: $2.68^*
Shares after: 75,094
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $701,092
Shares: -20,000
Change %: -27%
Price: $35.05
Shares after: 55,094
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -20,000
Change %: -32%
Price: $0.000000
Shares after: 42,201
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $2.68
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.

Footnote F2

Includes 44,276 restricted stock units.

Footnote F3

This transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.